![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Lead Product(s): ASN90
Therapeutic Area: Neurology Product Name: ASN90
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ferrer Internacional
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 22, 2023
Details:
The grant will fund a preclinical proof-of-concept study to assess the disease-modifying properties of Asceneuron’s OGA inhibitor ASN51 in a preclinical model of inherited PD.
Lead Product(s): ASN51
Therapeutic Area: Neurology Product Name: ASN51
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson’s Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding May 03, 2022
Details:
Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's model.
Lead Product(s): ASN90
Therapeutic Area: Neurology Product Name: ASN90
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathic disease, progressive supranuclear palsy (PSP), and was granted Orphan Drug Designation by the US FDA for the treatment of Progressive Supranuclear Palsy (PSP).
Lead Product(s): ASN120290
Therapeutic Area: Neurology Product Name: ASN120290
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021